Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531425 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
A Phase 1 study, sponsored by OncoSec Medical Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02531425 is a Phase 1 study that has completed, run by OncoSec Medical Incorporated. The registered enrollment target is 10 participants.
The verdict
NCT02531425, a Phase 1 study, has completed, sponsored by OncoSec Medical Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) followed immediately by electroporation (EP), into accessible tumor lesions. IT-pIL12-EP will be administered in Days 1, 5, and 8 of the single 28-day cycle.
Interventions
- BIOLOGICAL IT-pIL12-EP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531425
The ClinicalTrials.gov registry entry for NCT02531425 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoSec Medical Incorporated, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IT-pIL12-EP is the first listed.
NCT02531425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02531425 about?
NCT02531425 is a clinical study titled "Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC". Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) fo...
What is the current status of trial NCT02531425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-09. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02531425?
The interventions under investigation include: IT-pIL12-EP (BIOLOGICAL).
Who is sponsoring clinical trial NCT02531425?
This trial is sponsored by OncoSec Medical Incorporated, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.